published meta-analysis   sensitivity analysis   studies

second booster dose in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsArbel / Magen, 2022 0.22 [0.17; 0.28] 0.22[0.17; 0.28]Arbel / Magen, 202210%NAnot evaluable deaths (time to event analysis only)detailed resultsArbel / Magen, 2022 0.22 [0.17; 0.28] 0.22[0.17; 0.28]Arbel / Magen, 202210%NAnot evaluable confirmed COVID (any severity)detailed resultsArbel / Magen, 2022 0.55 [0.54; 0.57] Bar-On, 2022 0.47 [0.46; 0.48] Cohen, 2022 0.56 [0.50; 0.63] Regev-Yochay (Comirnaty), 2022 0.70 [0.45; 1.09] Regev-Yochay (Spikevax), 2022 0.89 [0.56; 1.43] 0.55[0.49; 0.62]Arbel / Magen, 2022, Bar-On, 2022, Cohen, 2022, Regev-Yochay (Comirnaty), 2022, Regev-Yochay (Spikevax), 2022594%30,124NAnot evaluable hospitalizationdetailed resultsArbel / Magen, 2022 0.32 [0.25; 0.40] 0.32[0.25; 0.40]Arbel / Magen, 202210%NAnot evaluable symptomatic Covid-19detailed resultsArbel / Magen, 2022 0.45 [0.43; 0.48] Bar-On, 2022 0.34 [0.27; 0.42] Regev-Yochay (Comirnaty), 2022 0.57 [0.34; 0.94] Regev-Yochay (Spikevax), 2022 0.69 [0.40; 1.19] 0.45[0.36; 0.57]Arbel / Magen, 2022, Bar-On, 2022, Regev-Yochay (Comirnaty), 2022, Regev-Yochay (Spikevax), 2022469%513NAnot evaluable severe COVID-19 occurrencedetailed resultsArbel / Magen, 2022 0.38 [0.27; 0.53] Bar-On, 2022 0.34 [0.27; 0.42] 0.35[0.29; 0.42]Arbel / Magen, 2022, Bar-On, 202220%NAnot evaluable0.02.01.0relative treatment effectwww.metaEvidence.org2024-04-28 02:12 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 1316,1341,1342,1343 - roots T: 290